ISSN: 1080-6059
Neelam Taneja,
Arti Mishra, Garima Sangar, Gagandeep Singh, and Meera Sharma
Author affiliation: Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
Suggested citation for this article
To the Editor: Vibrio cholerae O1, the causative agent of cholera, has 2 biotypes (classical and El Tor), which have traditionally been distinguished by phenotypic tests and by genetic differences in the major toxin-coregulated pilus (TCP) gene, the tcpA allele of the TCP cluster (1), the rstR region (regulatory region for phage lysogeny) of CTX phages (2), the type of cholera toxin (CT) produced, and the infection pattern of the disease they cause. However, 3 variants of the El Tor biotype have been described recently: Matlab (a place in Bangladesh) variants in 2002 (3), which could not be biotyped because they have a mixture of both classical and El Tor (4), Mozambique variant in 2004–2005, which has a typical El Tor genome but a tandem repeat of the classical CTX prophage in the small chromosome (5), and the altered El Tor type (a typical El Tor biotype and an El Tor CTX prophage that produces CT of the classical type) predominant in Bangladesh since 2001 (6). Hybrid vibrios have also been described in other regions of Asia and Africa (7).
CT, encoded by the ctxA and ctxB genes, is the principal toxin produced by V. cholerae O1 and O139. Methods for differentiating the biotype-specific CT-B subunit of V. cholerae O1 include sequencing the ctxB gene, performing an ELISA wth a monoclonal antibody specific to the classical or El Tor CT, or by using a mismatch amplification mutation assay (MAMA)–PCR to distinguish between 2 kinds of ctxB genes. This assay detects sequence polymorphisms based on nt position 203 of the ctxB gene (8).
In Punjab and Haryana states of northern India, during July–September 2007, 6 clusters of cholera outbreak were identified. A total of 745 case-patients were admitted to local government hospitals; the cholera attack rate was 183/1,000 population. Four deaths were reported (case-fatality rate 0.5%). The number of cases per cluster varied from 15 to 400, and adults were primarily affected (74%); 20% of patients had severe dehydration. V. cholerae O1 Ogawa was confirmed from stool cultures by using standard isolation, biochemical, and serotyping methods. Twenty-six isolates were phenotypically and genotypically characterized according to biotype. Phenotypic characterization included the Voges-Proskauer reaction, polymyxin B (50 U) susceptibility, chick cell agglutination, and sheep erythrocyte hemolysis; all isolates were confirmed as El Tor biotype. Genotypic characterization included PCR assays for ctxA and tcpA (2), rstR (3), and ctxB (8). All strains were toxigenic because each carried the ctxA gene. All strains also carried El Tor–specific tcpA (472 bp) and rstR genes (500 bp). MAMA-PCR showed the ctxB gene of both El Tor and the classical type in 21 (80%) of 26 isolates tested.
Similarly, we also tested 20 available isolates from the 2002 outbreak and 4 and 19 sporadic isolates from 2003 and 2004, respectively; all were phenotypically and genotypically confirmed as El Tor and had only ctxB of the El Tor type. Of 53 water samples tested during the 2007 outbreak, 4 grew V. cholerae. Three samples were confirmed to be non-O1, non-O139 strains. Only 1 isolate was V. cholerae O1, which was positive for tcp, ctxA, and ctxB of both classical and El Tor types (Table).
During the cholera outbreak of 2002 in Chandigarh (9), only 1 death was reported (case-fatality rate, <0.01%); the attack rate was 20/1,000, 58.6% were children, and only 10% had severe dehydration. Before the most recent outbreak, the affected regions of Panjab and Haryana (Ambala, Nurpur, Kurali, Mohali, Panchkula, and Raili) had been free of cholera outbreaks since 1994, though sporadic cases had been reported. The 4 deaths from cholera in 2007, along with adult preponderance, high attack rate, more severe illness, and 6 different clusters, point towards a change in the disease's epidemiology. This change may be related to circulation of the hybrid vibrios in this region. In Bangladesh, all strains of V. cholerae O1 examined since 2001 belong to the altered El Tor type (6), which produces CT of the classical type. This altered type has replaced the seventh pandemic strain of the El Tor biotype that produced CT of the El Tor type, which indicates that a cryptic change has occurred in the seventh pandemic El Tor biotype strains of V. cholerae O1.
Newly emerged variants from Bangladesh (8) have the genetic makeup of El Tor with ctxB gene of only classical, whereas our strains are unique in having ctxB of both the classical and El Tor biotypes. Our strains appear to be different from the Mozambique variant V. cholerae O1 (10), which has rstR of the classical type, in that our strains have rstR of only the El Tor type. Of 5 Matlab variants analyzed with MAMA-PCR, 3 had classical ctxB and 2 had El Tor type. Our study highlights the different genetic recombinations possible in V. cholerae and the epidemiologic role of these recombinations.
We thank the JICA-National Institute of Cholera and Enteric Diseases (NICED) training programme, NICED Kolkata for providing control classical El Tor and hybrid Vibrio cholerae O1, and local health authorities and hospitals for providing access to patients and data.
Taneja N, Mishra A, Sangar G, Singh G, Sharma M. Outbreaks caused by new variants of Vibrio cholerae O1 El Tor, India [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Feb [date cited]. Available from http://www.cdc.gov/EID/content/15/2/352.htm
DOI: 10.3201/eid1502.080943
Please use the form below to submit correspondence to the authors or contact them at the following address:
Neelam Taneja, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh.PIN-160012, India; email: drneelampgi@yahoo.com
Please contact the EID Editors at eideditor@cdc.gov
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
This page posted January 28, 2009
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435